| pubmed-article:3335027 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3335027 | lifeskim:mentions | umls-concept:C1704628 | lld:lifeskim |
| pubmed-article:3335027 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3335027 | lifeskim:mentions | umls-concept:C1448177 | lld:lifeskim |
| pubmed-article:3335027 | lifeskim:mentions | umls-concept:C1511636 | lld:lifeskim |
| pubmed-article:3335027 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3335027 | pubmed:dateCreated | 1988-2-23 | lld:pubmed |
| pubmed-article:3335027 | pubmed:abstractText | A synergistic increase in the cytotoxic effects of recombinant human tumor necrosis factor (rH-TNF) and hyperthermia was demonstrated both in vitro and in vivo. The cytotoxicity of rH-TNF against L-M cells in incubation for 12 h at 38.5 and 40 degrees C based on the concentration necessary for 50% cytotoxicity was, respectively, 125 and more than 500 times as high as in similar incubation at 37 degrees C. As observed 18 days after implantation of Meth-A fibrosarcoma cells in mice, single i.v. administration of rH-TNF at 1000 units/mouse resulted in complete cures in five mice when performed in combination with hyperthermia (40 degrees C), whereas rH-TNF alone in the same dose resulted in 27.1% inhibition of tumor growth and hyperthermia alone had no appreciable effect on tumor growth. The i.v. administration of rH-TNF three times at 100 or 300 units/mouse together with hyperthermia (40 degrees C) resulted in 41.2 and 89.0% tumor growth inhibition, respectively; similar administration without hyperthermia appeared to have little or no appreciable effect on tumor growth. The results suggest that combination therapy including rH-TNF and hyperthermia may be of value in the treatment of malignancy in human patients. | lld:pubmed |
| pubmed-article:3335027 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3335027 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335027 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3335027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335027 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3335027 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:3335027 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:MaedaMM | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:WatanabeNN | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:SoneHH | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:UrushizakiII | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:NiitsuYY | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:YamauchiNN | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:UmenoHH | lld:pubmed |
| pubmed-article:3335027 | pubmed:author | pubmed-author:NedaHH | lld:pubmed |
| pubmed-article:3335027 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3335027 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:3335027 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:3335027 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3335027 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3335027 | pubmed:pagination | 650-3 | lld:pubmed |
| pubmed-article:3335027 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:meshHeading | pubmed-meshheading:3335027-... | lld:pubmed |
| pubmed-article:3335027 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3335027 | pubmed:articleTitle | Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. | lld:pubmed |
| pubmed-article:3335027 | pubmed:affiliation | Department of Internal Medicine, Sapporo Medical College, Japan. | lld:pubmed |
| pubmed-article:3335027 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335027 | lld:pubmed |
